Certara appoints Nathan Teuscher to lead Phoenix software division

Phoenix is used to analyse the safety and efficacy of drugs under development

Certara, the leading provider of decision support technology and consulting services to optimise drug development and improve health outcomes, announces the appointment of Nathan Teuscher, PhD, to Vice President of Pharmacometric Solutions.

In his new role, Dr Teuscher will lead the company’s Phoenix software division. He previously served as Certara’s Vice President of Scientific Training.

Dr Teuscher is the former founder and president of clinical pharmacology consultancy PK/PD Associates, which Certara acquired in August 2015.

‘A customer-centric professional, Dr Teuscher is both a renowned modeller and an accomplished educator in the field of pharmacometrics,’ said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. ‘This appointment will facilitate the Phoenix software platform’s evolution and also support our goal of further engaging the industry about the benefits and usage of modelling and simulation in drug development.’

Dr Teuscher has held leadership roles in the pharmaceutical industry as a scientist, consultant and teacher in pharmacokinetics, clinical pharmacology and pharmacometrics. Early in his career, Dr Teuscher was recognised as a Computerworld Smithsonian Laureate for his work on developing a pioneering web-application to teach pharmacokinetics to pharmacy students at the University of Michigan. Since that time, he has developed many educational tools, including mobile and web applications for pharmacometric analyses.

Phoenix is the pharmaceutical industry’s premier software platform for managing, analysing and reporting pharmacokinetic (PK), pharmacodynamic (PD) and toxicokinetic data. It is used to analyse the safety and efficacy of drugs under development by pharmaceutical, veterinary and academic researchers, and the US Food and Drug Administration and other global regulatory agencies.

Phoenix WinNonlin, considered to be the industry’s ‘gold standard’ for non-compartmental analysis, is used by 6000 researchers in 50 countries.

Companies